Correction to Lancet HIV 2018; DOI:10.1016/S2352-3018(18)30092-4
- PMID: 29941406
- DOI: 10.1016/S2352-3018(18)30147-4
Correction to Lancet HIV 2018; DOI:10.1016/S2352-3018(18)30092-4
Erratum for
-
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18. Lancet HIV. 2018. PMID: 29925489 Clinical Trial.
Similar articles
-
Correction to Lancet HIV 2019; published online Aug 23. https://doi.org/10.1016/S2352-3018(19)30274-7.Lancet HIV. 2019 Dec;6(12):e815. doi: 10.1016/S2352-3018(19)30320-0. Epub 2019 Sep 24. Lancet HIV. 2019. PMID: 31562056 No abstract available.
-
Correction to Lancet HIV 2019; published online Aug 28. https://doi.org/10.1016/S2352-3018(19)30293-0.Lancet HIV. 2019 Dec;6(12):e815. doi: 10.1016/S2352-3018(19)30321-2. Epub 2019 Sep 24. Lancet HIV. 2019. PMID: 31562057 No abstract available.
-
Correction to Lancet HIV 2020; published online Feb 17. https://doi.org/10.1016/S2352-3018(20)30001-1.Lancet HIV. 2020 Dec;7(12):e803. doi: 10.1016/S2352-3018(20)30072-2. Epub 2020 Feb 28. Lancet HIV. 2020. PMID: 32119821 No abstract available.
-
Correction to Lancet HIV 2020; published online Jan 14. https://doi.org/10.1016/S2352-3018(19)30378-9.Lancet HIV. 2020 Dec;7(12):e803. doi: 10.1016/S2352-3018(20)30041-2. Epub 2020 Feb 6. Lancet HIV. 2020. PMID: 32035515 Free PMC article. No abstract available.
-
Correction to Lancet HIV 2024; published online Aug 16. https://doi.org/10.1016/S2352-3018(24)00173-5.Lancet HIV. 2024 Dec;11(12):e804. doi: 10.1016/S2352-3018(24)00232-7. Epub 2024 Aug 29. Lancet HIV. 2024. PMID: 39217994 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources